JP2013529619A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529619A5
JP2013529619A5 JP2013515902A JP2013515902A JP2013529619A5 JP 2013529619 A5 JP2013529619 A5 JP 2013529619A5 JP 2013515902 A JP2013515902 A JP 2013515902A JP 2013515902 A JP2013515902 A JP 2013515902A JP 2013529619 A5 JP2013529619 A5 JP 2013529619A5
Authority
JP
Japan
Prior art keywords
chloropyrimidin
thiazol
tert
butyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013515902A
Other languages
English (en)
Other versions
JP2013529619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/060561 external-priority patent/WO2011161216A1/en
Publication of JP2013529619A publication Critical patent/JP2013529619A/ja
Publication of JP2013529619A5 publication Critical patent/JP2013529619A5/ja
Pending legal-status Critical Current

Links

Description

工程3. N−(3−(2−tert−ブチル−5−(2−クロロピリミジン−4−イル)チアゾール−4−イル)−2−フルオロフェニル)メタンスルホンアミドの製造:
表題中間体を、3−(2−tert−ブチル−5−(2−クロロピリミジン−4−イル)チアゾール−4−イル)−2−フルオロアニリンから、出発物質IV、工程3の製造に使用したスルホニル化法に従い、溶媒としてピリジンを使用して製造した:LCMS(m/z): 441.1(MH+), tR = 1.04 min。
JP2013515902A 2010-06-25 2011-06-23 タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物 Pending JP2013529619A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35860310P 2010-06-25 2010-06-25
US61/358,603 2010-06-25
US36853410P 2010-07-28 2010-07-28
US61/368,534 2010-07-28
PCT/EP2011/060561 WO2011161216A1 (en) 2010-06-25 2011-06-23 Heteroaryl compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2013529619A JP2013529619A (ja) 2013-07-22
JP2013529619A5 true JP2013529619A5 (ja) 2014-07-24

Family

ID=44280749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515902A Pending JP2013529619A (ja) 2010-06-25 2011-06-23 タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物

Country Status (11)

Country Link
US (1) US20130096149A1 (ja)
EP (1) EP2585454A1 (ja)
JP (1) JP2013529619A (ja)
KR (2) KR20140117684A (ja)
CN (1) CN103080107A (ja)
AU (1) AU2011268906A1 (ja)
BR (1) BR112012032884A2 (ja)
CA (1) CA2803055A1 (ja)
EA (1) EA201201676A1 (ja)
MX (1) MX2012015100A (ja)
WO (1) WO2011161216A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199979B2 (en) * 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
US20190263796A1 (en) 2016-09-23 2019-08-29 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
CN114746419B (zh) * 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
CN111320548B (zh) * 2020-04-24 2022-10-18 浦拉司科技(上海)有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
US20240101516A1 (en) * 2021-01-20 2024-03-28 Basf Se Synthesis of polyfluorinated aryl and heteroaryl carboxamides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0910401A1 (en) 1996-05-23 1999-04-28 Applied Research Systems ARS Holdings N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
JP2003063993A (ja) * 2001-06-11 2003-03-05 Takeda Chem Ind Ltd 医薬組成物
ES2549159T3 (es) 2002-03-13 2015-10-23 Array Biopharma, Inc. Derivados de bencimidazol N3-alquilados como inhibidores de MEK
US7666901B2 (en) 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
CA2599212A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド mTOR阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
SI2057156T1 (sl) 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
BRPI0814423B1 (pt) * 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
WO2009076140A1 (en) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) * 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2013529619A5 (ja)
JP2010505891A5 (ja)
JP2014138100A5 (ja)
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
DK2683708T3 (da) Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
DK3034497T3 (da) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-penta-hydroxyhexyl)amino)ethoxy)phenyl)butyl) carbamimidoyl)pyrazin-2-carboxamid
JP2015512729A5 (ja)
JP2015522045A5 (ja)
JP2013514381A5 (ja)
TWD159624S (zh) 溫度計(一)之部分
JP2013522425A5 (ja)
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
BR112015023218A2 (pt) formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof
EA201370149A1 (ru) Антагонисты рецептора
JP2016540026A5 (ja)
WO2017015433A3 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
SMT201500069B (it) Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide
IL253239A0 (en) Method for preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[5,4[b-pyridin-2-yl)pyridin-2-amine
MX2015015173A (es) N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas.
JP2017092104A5 (ja)
JP2017518319A5 (ja)
JP2010208011A5 (ja)
WO2011047390A3 (en) Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus
TH93566B (th) อิฐบล็อก